This study is an open-label, randomized, pilot comparison of the effects of either lopinavir/ritonavir or efavirenz in combination with tenofovir plus emtricitabine on cholesterol metabolism, mitochondrial functioning and immune response in 50 naive HIV patients after 48 weeks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
50
Tenofovir 300 mg + emtricitabine 200 mg, (Truvada, Gilead Sciences) \+ Efavirenz 600 mg, (Sustiva, Bristol-Myers Squibb) once daily
Tenofovir 300 mg + emtricitabine 200 mg, (Truvada, Gilead Sciences)QD Lopinavir/ritonavir 400 mg/100 mg, (Kaletra, Abbott) BID
Hospital Germans Trias i Pujol
Badalona, Barcelona, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Barcelona, Spain
Hospital Clinic
Barcelona, Barcelona, Spain
Hospital Universitario Virgen del Rocío
Seville, Sevilla, Spain
Changes in total cholesterol and HDL and LDL fractions
Time frame: 48 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Hospital Joan XXIII
Tarragona, Tarragona, Spain